Nonproliferative Diabetic Retinopathy

Presentations from the virtual Association for Research in Vision and Ophthalmology meeting were released in May and June.

Eyes with moderately severe to severe baseline diabetic retinopathy without prior panretinal photocoagulation experienced more rapid improvements from ranibizumab treatment compared with eyes with more mild or severe diabetic retinopathy, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.

Two-year results of the PANORAMA study show consistently better results with intravitreal aflibercept injection vs. sham in moderately severe to severe nonproliferative diabetic retinopathy.

The 2-year results of the phase 3 PANORAMA trial evaluating intervention with aflibercept for patients with moderately severe to severe nonproliferative diabetic retinopathy showed consistent treatment greatly prevented serious vision-threatening complications and improved Diabetic Retinopathy Severity Scale scores.

Ophthalmology’s armamentarium in the United States grew in 2019 with FDA approvals in retina and glaucoma treatment, as well as an approval for the first trifocal IOL.

MEXICO CITY — Results from a 2-year follow-up of patients with nonproliferative diabetic retinopathy suggest intravitreal sulfur hexafluoride injection to induce posterior vitreous detachment may slow the progression of the eye disease.